Lyra Therapeutics (LYRA) Accumulated Expenses (2019 - 2025)

Lyra Therapeutics (LYRA) has reported Accumulated Expenses for 7 consecutive years, with $257000.0 the latest figure, recorded in Q4 2025.

• Accumulated Expenses for Q4 2025 came in at $257000.0, down 51.42% year-over-year; the trailing twelve-month figure through Dec 2025 was $257000.0 (down 51.42% YoY), and the FY2025 annual result was $257000.0, down 51.42% from the prior year.
• Accumulated Expenses for Q4 2025 stood at $257000.0, down from $3.1 million in the prior quarter.
• The five-year high for Accumulated Expenses was $11.1 million in Q3 2023, with the low at $257000.0 in Q4 2025.
• A 5-year average of $4.0 million and a median of $3.1 million in 2022 frame the typical range for Accumulated Expenses.
• Across the five-year window, Accumulated Expenses surged 343.12% in 2023 and slumped 88.67% in 2024, its largest moves.
• Lyra Therapeutics' Accumulated Expenses stood at $2.4 million in 2021, then grew by 22.48% to $3.0 million in 2022, then soared by 56.97% to $4.7 million in 2023, then tumbled by 88.67% to $529000.0 in 2024, then slumped by 51.42% to $257000.0 in 2025.
• The last three Accumulated Expenses figures came in at $257000.0 (Q4 2025), $3.1 million (Q3 2025), and $3.5 million (Q2 2025), per Business Quant data.